Decision on future reimbursement status of medicinal products in ATC groups A04 and A03FA
On 25 November 2009, the Danish Medicines Agency made a decision on the future reimbursement status of medicinal products in ATC group A04 (antiemetics and antinauseants) and medicinal products in ATC group A03FA (propulsives).
As of 14 December 2009, metoclopramide (A03FA01) tablets and hard prolonged-release capsules and domperidone (A03FA03) tablets are eligible for general reimbursement. The reimbursement status of the remaining medicinal products is unaltered.
Via the box, you can find a link to the decision and the letter which the Danish Medicines Agency has sent to companies holding a marketing authorisation for medicinal products comprised by the decision (in Danish only).
For further information, please contact the Reimbursement Department at Send an email.